Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Cortesi, Laura ^a   Masini, Cristina ^a   Cirilli, Claudia ^b   Medici, Veronica ^a   Marchi, Isabella ^a   Cavazzini, Giovanna ^c   Pasini, Giuseppe ^d   Turchetti, Daniela ^e   Federico, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b MODENA CANCER REGISTRY   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

^d City Hospital   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY BREAST CANCER; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL TIME; ADULT; BREAST TUMOR; ETHNOLOGY; FAMILY HEALTH; GENETIC PREDISPOSITION; GENETICS; ITALY; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY HEALTH; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ITALY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 77949462817     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-90     Document Type: Article

References (22)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71. 10.1126/science.7545954, 7545954.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378(6559):789-792. 10.1038/378789a0, 8524414.
3. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997, 3(12 Pt 1):2465-2469.
4. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelenat H, Pouillart P, Vincent-Salomon A, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000, 18(24):4053-4059.
5. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000, 11(3):307-313. 10.1023/A:1008340723974, 10811497.
6. Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003, 97(3):527-536. 10.1002/cncr.11080, 12548593.
7. Hampl JA, Hampl M, Reiss G, Koch R, Saeger HD, Schackert HK. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients. Anticancer Res 2004, 24(1):281-290.
8. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007, 357(2):115-123. 10.1056/NEJMoa070608, 17625123.
9. Cortesi L, Turchetti D, Bertoni C, Bellei R, Mangone L, Vinceti M, Federico M, Silingardi V, Ferrari S. Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromosomes Cancer 2000, 27(2):130-135. 10.1002/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U, 10612800.
10. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26(14):2126-2132. 10.1038/sj.onc.1210014, 17016441.
11. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006, 25(43):5846-5853. 10.1038/sj.onc.1209876, 16998499.
12. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004, 6(1):R8-R17. 10.1186/bcr658, 314444, 14680495.
13. Bonadona V, Dussart-Moser S, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, Bremond A, Treilleux I, Martin A, Romestaing P, et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 2007, 101(2):233-245. 10.1007/s10549-006-9288-7, 17061047.
14. Cortesi L, Turchetti D, Marchi I, Fracca A, Canossi B, Battista R, Ruscelli S, Pecchi AR, Torricelli P, Federico M. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer 2006, 6:210. 10.1186/1471-2407-6-210, 1578585, 16916448.
15. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003, 88(8):1285-91. 10.1038/sj.bjc.6600859, 2747554, 12698198.
16. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275(31):23899-23903. 10.1074/jbc.C000276200, 10843985.
17. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003, 22(5):1169-1173.
18. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002, 8(12):571-576. 10.1016/S1471-4914(02)02434-6, 12470990.
19. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96(22):1659-1668.
20. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004, 279(53):55117-55126. 10.1074/jbc.M404524200, 15498778.
21. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921. 10.1038/nature03445, 15829967.
22. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002, 39(8):608-610. 10.1136/jmg.39.8.608, 1735193, 12161606.